Bemiparin in neonatal thrombosis: therapeutic dosing and safety.

Autor: Sanchez-Holgado M; Department of Neonatology. La Paz University Hospital, Madrid, Spain. msholgado@salud.madrid.org., Sampedro M; Department of Neonatology. La Paz University Hospital, Madrid, Spain., Zozaya C; Department of Neonatology. La Paz University Hospital, Madrid, Spain., Permuy Romero C; Department of Neonatology. La Paz University Hospital, Madrid, Spain., Alvarez-Garcia P; Department of Neonatology. La Paz University Hospital, Madrid, Spain., La Banda-Montalvo L; Department of Neonatology. La Paz University Hospital, Madrid, Spain., Nieto C; Department of Neonatology. La Paz University Hospital, Madrid, Spain., Pellicer A; Department of Neonatology. La Paz University Hospital, Madrid, Spain.
Jazyk: angličtina
Zdroj: Journal of perinatology : official journal of the California Perinatal Association [J Perinatol] 2024 Dec 16. Date of Electronic Publication: 2024 Dec 16.
DOI: 10.1038/s41372-024-02200-1
Abstrakt: Objective: To evaluate the therapeutic dose and safety of bemiparin in neonatal thrombosis treatment.
Study Design: A retrospective review was conducted on infants treated with bemiparin between 2018 and 2023 at a tertiary hospital.
Results: 72 neonates with a mean gestational age of 37 weeks were included. Twenty were preterm, with a median gestational age of 33.5 weeks and a median birth weight of 1847.5 grams. The mean (SD) initial and therapeutic bemiparin doses were 170.5 (31) and 200 (37.2) IU/kg/day, respectively. Only 32% of patients reached the therapeutic target range (TTR) with the initial dose. Preterm infants required higher doses to reach TTR (215 vs 194.7 IU/kg/day, p = 0.05). Adverse events were minimal (1.4%) and unrelated to the starting dose or prematurity.
Conclusion: Bemiparin appears to be a potential therapeutic option for anticoagulation in neonates; however, targeted anti-Xa levels were rarely achieved with the initial dose and most patients required uptitration.
Competing Interests: Competing interests: The authors declare no competing interests. Ethical approval: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of La Paz University Hospital (ethical approval code HULP: PI-5859, date 21 September 2023). Informed consent: Given the retrospective nature of the study, informed consent from participants was not required.
(© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)
Databáze: MEDLINE
Externí odkaz: